Yhdysvallat - englanti - NLM (National Library of Medicine)

american health packaging - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene or amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of h

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for injection 20ml vials (torbay pharmaceuticals - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for infusion 50ml vials (torbay pharmaceuticals - magnesium sulfate heptahydrate - solution for infusion - 500mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for injection 2ml ampoules (torbay pharmaceuticals - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for injection 5ml ampoules (torbay pharmaceuticals - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for injection 10ml ampoules (torbay pharmaceuticals - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml

Yhdysvallat - englanti - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 80 mg in 1 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively.  when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant.  however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

Yhdysvallat - englanti - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 4 g in 100 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

Yhdysvallat - englanti - NLM (National Library of Medicine)

exela pharma sciences, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Yhdysvallat - englanti - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 4 g in 50 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.